The Brain Metastases Consortium facilitates collaborative research between the many exceptional researchers and clinicians at Stanford University. These projects involve specialists from different departments, whose synergistic talents and interests when combined, exponentially advance our understanding of, and capacity to treat, metastatic brain tumors. Interests include cancer biology, radiation oncology, neuroscience, immunology, medical oncology, neurosurgery, physics, bio-engineering, neuro oncology, and population science, among others. 


Featured Publications:

Response of a pre-clinical model of breast cancer leptomeningeal disease to the novel, brain-permeant chemotherapeutic QBS10072S.

Authors: Deng J, Chernikova S, Wang Y, Rodriguez M, Anderson SJ, Umeh-Garcia MC, Godfrey BO, Ahmadian SS, Fischer WN, Koller KJ, Jandeleit B, Ringold G, Hayden Gephart M. 

Published: Molecular Cancer Therapeutics, October 2021

Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases.

Authors: Li Y, Polyak D, Lamsam L, Connolly I, Johnson E, Khoeur L, Stanley G, Zhang Y, Liu B, Nagpal S, Hayden Gephart M. 

Published: Nature Precision Oncology, October 2021


Financial toxicity in patients with brain and spine metastases.
Koenig JL, Sandhu N, Sborov K, Sabloch A, Usoz M, Li G, Hayden Gephart M, Chang S, Hiniker S, Soltys SG, Pollom EL.
Published: World Neurosurgery, July 2021

Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M, Rodrigues AJ, Pollom EL, Gibbs IC, Soltys SG, Hancock SL, Neal JW, Padda SK, Ramchandran KJ, Wakelee HA, Chang SD, Lim M, Hayden Gephart M, Li G.  
Published: Journal of Neuro Oncology, March 2021